News | April 06, 2022
AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain
The new facility is scheduled to start operation in the first half of 2024
The new facility is scheduled to start operation in the first half of 2024
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The plant is scheduled to come on stream in September 2024
Fujifilm has been at the forefront of medical imaging and healthcare informatics. It’s developing new AI platforms to address medical challenges. Chander Shekhar Sibal, Sr. Vice-President, Fujifilm India gives us an insight in an interview with Thomas C. Thottathil, Editor, indianpharmapost.com
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
_256_384.jpg)
Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Subscribe To Our Newsletter & Stay Updated
